FavRem: Antiviral Drugs on the Treatment of SARS-CoV-2

• Sponsor: Astana Medical University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04727775
• Collaborator: (none)
• Enrollment: 150
• Locations: 2
• Anticipated Duration (Months): 24.8
• Patients Per Site: 75
• Patients Per Site Per Month: 3

Study Details

Study Description

Brief Summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Condition or Disease	Intervention/Treatment	Phase
Complication of Medical Care; Pneumonia, Viral	Drug: Favipiravir; Drug: Remdesivir

Detailed Description

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Study Design

• Study Type: Observational
• Anticipated Enrollment: 150 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19
• Actual Study Start Date: Dec 1, 2020
• Anticipated Primary Completion Date: Nov 25, 2022
• Anticipated Study Completion Date: Dec 25, 2022

Arms and Interventions

Arm	Intervention/Treatment
Complications Evaluathion	Drug: Favipiravir; Antiviral drugs; Drug: Remdesivir; Antiviral drugs
Oxygen status Evaluathion	Drug: Favipiravir; Antiviral drugs; Drug: Remdesivir; Antiviral drugs
Oxugen support Evaluathion	Drug: Favipiravir; Antiviral drugs; Drug: Remdesivir; Antiviral drugs

Outcome Measures

Primary Outcome Measures

1. Outcome without comlications [14 days]

   The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

Secondary Outcome Measures

1. Heart rate [14 days]

   Measure

2. SpO2 [14 days]

   Measure

3. Blood pressure [14 days]

   Measure

4. Respiratory rate [14 days]

   Measure

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

main group

• Patients with COVID19 with medium and easy condition disease

• take favipiravir/remdisivir control group

• Patients with COVID19 with medium and easy condition disease

• not take favipiravir/remdisivir

Exclusion Criteria:

• patients younger 18

• severe conditionis

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Aidos Konkaev	Nur-Sultan		Kazakhstan	010000
2	Semey Medical University	Semey		Kazakhstan	071407

Sponsors and Collaborators

• Astana Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Aidos Konkayev, doctor, Astana Medical University
• ClinicalTrials.gov Identifier: NCT04727775
• Other Study ID Numbers: AMU
• First Posted: Jan 27, 2021
• Last Update Posted: Jul 20, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pneumonia, Viral; Favipiravir; Remdesivir

Study Results

No Results Posted as of Jul 20, 2022